Incidence of Recurrent Invasive Pneumococcal Disease in Canada - Report - MDSpire

Incidence of Recurrent Invasive Pneumococcal Disease in Canada

  • By

  • Leah J. Ricketson

  • Altynay Shigayeva

  • Irina Rajakumar

  • Zoe Zhong

  • Kazi Hassan

  • Irene Martin

  • Alyssa Golden

  • Allison J. McGeer

  • James D. Kellner

  • Calgary Area Epidemiology Research Group and the Toronto Invasive Bacterial Diseases Network

  • Chingiz Amirov

  • Neil Rau

  • Danny Chen

  • Jeff Powis

  • Amna Faheem

  • Kevin Katz

  • Valerie Sales

  • Samir Patel

  • Abdelbaset Belhaj

  • Reena Lovinsky

  • David Rose

  • Christie Vermeiren

  • Tony Mazzulli

  • Jennie Johnstone

  • Karen Green

  • Michael Lingley

  • Andrew Simor

  • Samira Mubareka

  • Sigmund Krajden

  • Larissa Matukas

  • Sharon Walmsley

  • Medina Saffie

  • Daniel Ricciuto

  • Krystyna Ostrowska

  • David Richardson

  • Shannon N Pyra

  • Joslyn D Gray

  • July 7, 2026

  • 0 min

Share

Clinical Report: Prevalence of Recurrent Invasive Pneumococcal Disease Across Canada

Overview

This cohort study estimates the incidence of recurrent invasive pneumococcal disease (rIPD) in Canada and identifies associated risk factors.

Background

Invasive pneumococcal disease (IPD) is a leading cause of morbidity and mortality, even with vaccination programs in place. Recurrent IPD (rIPD) has a higher incidence compared to primary IPD.

Data Highlights

No numerical data available in the source material.

Key Findings

  • rIPD occurs in 2.2% to 5.3% of individuals with IPD.
  • The incidence of rIPD is estimated to be 27 times that of primary IPD.
  • Immunocompromising conditions are recognized risk factors for rIPD.
  • Current vaccination guidelines do not consider prior IPD as an indication for vaccination.
  • Active surveillance programs are essential for monitoring IPD incidence and serotype distribution.

Clinical Implications

Healthcare providers should be aware of the risk of rIPD, especially in immunocompromised patients. Continued surveillance and updated vaccination strategies are necessary to address the challenges posed by vaccine-evading serotypes.

Conclusion

The study highlights the ongoing prevalence of rIPD in Canada and the need for targeted prevention efforts, particularly among high-risk populations.

Related Resources & Content

  1. Incidence of Recurrent Invasive Pneumococcal Disease in Canada | Infectious Diseases | JAMA Network Open, 2023 -- Incidence of Recurrent Invasive Pneumococcal Disease in Canada
  2. Recommendations on the use of pneumococcal vaccines in adults, including PNEU-C-21 - Canada.ca, 2024 -- Recommendations on the use of pneumococcal vaccines in adults
  3. Invasive pneumococcal disease surveillance in Canada, 2023 - Canada.ca, 2023 -- Invasive pneumococcal disease surveillance in Canada
  4. Open Forum Infectious Diseases — The Burden of Invasive Pneumococcal Disease and the Effects of 7- and 13-Valent Pneumococcal Conjugate Vaccines in Singaporean Pediatric Population Over 24 Years
  5. Drugs - Real World Outcomes — Impact of the Prevnar 13 Childhood Vaccination Initiative in Alberta, Canada (2010–2015)
  6. Drugs - Real World Outcomes — Impact of the Prevnar 7 Immunization Initiative on Pneumococcal Serotype Distribution and Healthcare Expenses in Alberta (2003–2008)
  7. The Journal of Infectious Diseases — Distribution of Pneumococcal Serotypes and Evaluation of Current and Upcoming Pneumococcal Vaccines' Coverage
  8. Recommendations on the use of pneumococcal vaccines in adults, including PNEU-C-21 - Canada.ca
  9. Invasive pneumococcal disease surveillance in Canada, 2023 - Canada.ca
  10. Incidence of Recurrent Invasive Pneumococcal Disease in Canada | Infectious Diseases | JAMA Network Open | JAMA Network

Original Source(s)

Incidence of Recurrent Invasive Pneumococcal Disease in Canada

  • by Leah J. Ricketson, Altynay Shigayeva, Irina Rajakumar, Zoe Zhong, Kazi Hassan, Irene Martin, Alyssa Golden, Allison J. McGeer, James D. Kellner, Calgary Area Epidemiology Research Group and the Toronto Invasive Bacterial Diseases Network, Chingiz Amirov, Neil Rau, Danny Chen, Jeff Powis, Amna Faheem, Kevin Katz, Valerie Sales, Samir Patel, Abdelbaset Belhaj, Reena Lovinsky, David Rose, Christie Vermeiren, Tony Mazzulli, Jennie Johnstone, Karen Green, Michael Lingley, Andrew Simor, Samira Mubareka, Sigmund Krajden, Larissa Matukas, Sharon Walmsley, Medina Saffie, Daniel Ricciuto, Krystyna Ostrowska, David Richardson, Shannon N Pyra, Joslyn D Gray

  • July 7, 2026

Related Content

State-of-the-art of the high dose influenza vaccine in Spain

The Amish way of health care

Association between perfluoroalkyl and polyfluoroalkyl substances and response to the COVID-19 vaccine in a paediatric prospective observational cohort in Arizona